Canada Santé Publique: une majorité de Scientifiques fédéraux se disent muselés

90% des scientifiques estiment qu’ils ne peuvent pas parler librement aux médias de leur travail

Une majorité de scientifiques fédéraux se disent muselés
Des scientifiques fédéraux disent vivre dans un climat de peur…

Plus de 85 % des scientifiques du gouvernement fédéral croient qu’ils feraient face à de la censure ou des représailles s’ils se prononçaient publiquement contre une mesure de leur ministère susceptible de compromettre la santé et la sécurité publique ou de nuire à l’environnement.

Lisez Une majorité de scientifiques fédéraux se disent muselés
par Hugo de Grandpré, La Presse, 21 octobre 2013

Plus sur le BPA – pesticides – perturbateurs endocriniens

Vulvar Cancer: how I stayed Sane through my Medical Drama

The Cancer No One Talks About, by Darci Picoult

A New Lesson in Intimacy
Personal Stories

” …A day before the operation you will need to do a bowel cleanse…nothing to eat or drink after noon….after the operation, you will be in the hospital for a few days. Since a small piece of your urethra will be removed, you will have a catheter. Once you prove you can pee on your own, you will be sent home. You may be peeing on an angle for a while but that can be corrected.
No cardio exercise till you are healed.
…”

Continue reading: How I Stayed Sane Through My Medical Drama From the Author Who Had The Cancer No One Talks About
by Darci Picoult, journalist, DES daughter and author of My Virginia

About DES and Cancer:

More DES DiEthylStilbestrol Resources

Why change your Diet?

Cartoon by @pirarobizarro

Why change your DietDan Piraro is Cartoonist behind Bizarro and stand-up comic

Bisphenol-A affecting the Sperm Quality in Humans

BPA may affect sperm quality in couples seeking in vitro fertilization

Abstract:

Are urinary bisphenol A levels in men related to semen quality and embryo development after medically assisted reproduction?
ASRM is a non-profit organization devoted to advancing knowledge and expertise in reproductive medicine including infertility, menopause, and sexuality

Objective:
To evaluate whether urinary Bisphenol-A (BPA) levels in men adversely influence semen quality and embryo development after medically assisted reproduction.

Design:
Prospective, cohort study.

Setting:
University-based tertiary care center.

Patient(s):
A total of 149 couples undergoing their first or second IVF or intracytoplasmic sperm injection (ICSI) procedure.

Main Outcome Measure(s):
Semen quality and embryo development parameters until the blastocyst stage after the IVF or ICSI procedure.

Result(s):
Bisphenol A was detected in 98% (n = 146) of the samples with 0.1 ng/mL limit of detection. The geometric mean BPA concentration was 1.55 ng/mL. After the adjustment for potential confounders using linear regression models, an increase of natural logarithm transformed urinary BPA concentration was associated with lower natural logarithm transformed sperm count (β = −0.241, 95% confidence interval [CI] −0.470 to −0.012), natural logarithm transformed sperm concentration (β = −0.219, 95% CI −0.436 to −0.003), and sperm vitality (β = −2.660, 95% CI −4.991 to −0.329). The embryo development parameters from oocyte fertilization to the blastocyst formation stage were not affected by BPA exposure.

Conclusion(s):
Urinary BPA concentrations in male partners of subfertile couples may influence semen quality parameters, but do not affect embryo development up to the blastocyst stage after medically assisted reproduction.

Sources: Are urinary bisphenol A levels in men related to semen quality and embryo development after medically assisted reproduction?, The American Society for Reproductive Medicine,
PII: S0015-0282(13)03102-6, 30 Oct 2013

Analysis: BPA may affect sperm quality in couples seeking in vitro fertilization, EHN Staff, 14 Nov 2013

Our tags BPA – Endocrine Disruptors – Pesticides – Phthalates

Topamax and Birth Defects: Trial opens in Philadelphia

Janssen’s Topamax Users blame Drug for Birth Defects

Janssen's Topamax Users Blame Drug for Birth Defects
Bloomberg News is the first word in business and finance

Johnson & Johnson’s (JNJ) Janssen Pharmaceuticals failed to inform expectant mothers of risks that its epilepsy drug Topamax could cause birth defects, a lawyer for the mother of a Virginia 6-year-old told a jury. April Czimmer wouldn’t have taken Topamax for more than six months had she known the risks associated with the drug, her attorney Tommy Fibich said in opening statements today in state court in Philadelphia. Czimmer blames the drug for her son’s cleft palate and lip and claims Janssen negligently failed to inform patients about its risks until the U.S. Food and Drug Administration ordered stronger warnings in 2011. ”

Continue reading Janssen’s Topamax Users Blame Drug for Birth Defects, by Sophia Pearson, Bloomberg, 15 Oct 2013

All our posts tagged AEDsTopamaxTopiramateValproate

Science Weekly @AlokJha @GuardianScience Interview: Dr @BenGoldacre exposes Bad Pharma #SoundCloud

Alok Jha, Science correspondent at the Guardian and BBC TV presenter, speaks with Campaigner, Writer, Dr Ben Goldacre about his investigation into the pharmaceutical industry and his book Bad Pharma.

More information

Find out about the DES Drug tragedy

  • All our posts tagged DES and DES-exposed
  • Diethylstilbestrol, Journal of a DES Daughter logo website, stay updated with Like Journal of a DES Daughter on Facebook , Circle Journal of a DES Daughter on Google Plus , Follow @des_journal
  • Our DES video playlist on DES Daughter Network channel DES Diethylstilboestrol's channel on YouTube
  • See DES images on Flickr DES Diethylstilbestrol's photostream on Flickr and Pinterest Follow DES Daughter on Pinterest

Doctors are divided: how much to reveal about the Gifts they get from BigPharma

Why report the big consultancies but not the croissants?

head-in-dark image
The Global Mail Stories about Drug Money. Image via Zoltán Horlik.

” Doctors and other health professionals who accept lucrative consultancy fees, speaking fees, travel, accommodation and meals, royalties, shares and other major benefits from drug companies are to be publicly named.

But the recommendations of the Transparency Working Group (TWG) reluctantly set up by Australia’s peak pharmaceutical industry body, Medicines Australia, have left open the prospect of the pharmaceutical industry continuing to exert influence on health professionals in other ways. ” –   Continue reading:

Doctor, How Much Does Transparency Cost?
by Mike Seccombe, The Global Mail, 12 June 2013

Related posts:

Le Professeur Michel Tournaire commente l’étude Réseau DES France Distilbène 3 Générations de 2013

Vidéo par Réseau DES FRANCE DISTILBENE, 05 Nov 2013

Pour la première fois en France, une étude a été lancée pour permettre de déterminer les risques de cancer du sein chez les filles DES soumises in-utero à l’hormone de synthèse Distilbène®, ce médicament prescrit aux femmes enceintes jusqu’à la fin des années 70 et sensé prevenir les fausses couches. Le Professeur Michel Tournaire commente l’étude Distilbène trois générations menée en 2013 par l’association Réseau D.E.S. France.

  • Vidéo par Réseau DES FRANCE DISTILBENE, 05 Nov 2013
    • Pourquoi une nouvelle recherche sur le DES est-elle nécessaire en France?
    • Quelles sont les conséquences déjà connues pour ces filles DES?
    • Quelles sont les nouvelles inquiétudes pour les filles DES?
    • Quelles sont les buts de cette étude?
    • Comment assurer le succès de cette étude?
Le Distilbène DES, en savoir plus

La Fabrique du Mensonge, Industriels manipulant la Science nous mettant en Danger

Par Stéphane Foucart, journaliste scientifique au journal Le Monde

La Fabrique du Mensonge sur Flickr
Stéphane Foucart, journaliste scientifique au Monde, accessoirement auteur de livres inflammatoires

Un pan entier de l’activité des grandes entreprises consiste aujourd’hui à manipuler la science. Confrontés aux faits, les industriels utilisent le discours scientifique comme un instrument de propagande pour instiller le doute. Les fabricants de tabac sont les premiers à avoir recruté des faux experts, fait publier des études biaisées, organisé des fausses conférences scientifiques et corrompu des sociétés savantes afin de convaincre que le tabac n’était peut-être pas responsable du cancer du poumon. Les mêmes procédés ont été remis au goût du jour pour dédouaner l’amiante de ses méfaits, pour relativiser ou nier le réchauffement climatique, pour faire du déclin des abeilles un «mystère» sans lien avec les nouvelles générations d’insecticides. Ils sont également à l’œuvre dans l’affaire du bisphénol A, l’un des plus graves scandales sanitaires de ces dernières décennies. Quant au «débat» sur les OGM, cela fait bien longtemps qu’il n’a plus rien à voir avec la science. Les intérêts en jeu sont trop colossaux pour laisser les chercheurs s’exprimer librement… Au-delà de tout militantisme, La Fabrique du mensonge décortique les mécanismes de ces manœuvres et montre comment abîmer la science et détruire le savoir met nos vies en danger.

Thermography is Not a feasible Method for Breast Cancer Screening

The only study performed long ago for evaluating thermography technology in the screening setting demonstrated very poor result

Abstract:

Thermography is not a feasible method for breast cancer screening
Thermography uses heat sensitive infrared cameras to image the body and measure heat emission

Breast cancer is a common malignancy causing high mortality in women especially in developed countries. Due to the contribution of mammographic screening and improvements in therapy, the mortality rate from breast cancer has decreased considerably. An imaging-based early detection of breast cancer improves the treatment outcome. Mammography is generally established not only as diagnostic but also as screening tool, while breast ultrasound plays a major role in the diagnostic setting in distinguishing solid lesions from cysts and in guiding tissue sampling. Several indications are established for contrast-enhanced magnetic resonance imaging. Thermography was not validated as a screening tool and the only study performed long ago for evaluating this technology in the screening setting demonstrated very poor results. The conclusion that thermography might be feasible for screening cannot be derived from studies with small sample size, unclear selection of patients, and in which mammography and thermography were not blindly compared as screening modalities. Thermography can not be used to aspirate, biopsy or localize lesions preoperatively since no method so far was described to accurately transpose the thermographic location of the lesion to the mammogram or ultrasound and to surgical specimen. Thermography cannot be proclaimed as a screening method, without any evidence whatsoever.

Sources: Thermography is not a feasible method for breast cancer screening, NCBI, June 2013 ;37(2):589-93. – full study PDF

Related post: Is thermography a valid tool for breast cancer screening or snake oil? by Jen Gunter, 04 Oct 2013

For DES Daughters, and in the UK